Aurinia Pharmaceuticals Inc. Investment analysts at SVB Leerink issued their profits which are FY2022 share (EPS) estimates for shares of Aurinia Pharmaceuticals in an investigation note released on Tuesday, January nineteenth. SVB Leerink analyst J. Schwartz forecasts that the biotechnology business will earn ($0.23) per share for the entire year.
Aurinia Pharmaceuticals last circulated its earnings being quarterly on Sunday, November 15th. The biotechnology business reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). Aurinia Pharmaceuticals possessed a return that is negative equity of 36.98% and a negative net margin of 173,992.23per cent. The organization had income of $0.03 million for the quarter, set alongside the opinion estimate of $0.06 million.
A number of other equities research analysts have recently given reports on AUPH. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “buy” rating to an “accumulate” score in an investigation report on, November 3rd. HC Wainwright boosted their price target on Aurinia Pharmaceuticals from $28.00 to $30.00 and gave the business a “buy” rating in an investigation note on, December eighteenth.
Aurinia Pharmaceuticals went from the “sell” rating to a “hold” rating in an investigation note on, January 12th tuesday. Cantor Fitzgerald lowered their target price on Aurinia Pharmaceuticals from $30.00 to $26.00 in an investigation note on, November 12th thursday. Finally, Oppenheimer reissued a “buy” rating and set a $20.00 target price on shares of Aurinia Pharmaceuticals in a research note on, December seventeenth. Two equities research analysts have rated the stock by having a hold rating and six have granted a buy score to the organization’s stock. Aurinia Pharmaceuticals currently has a opinion score of “Buy” and a consensus price target of $22.14. Aurinia Pharmaceuticals Inc. Investment analysts gave it a buy rating.